Mr P, that’s very informative …thanks.

First 83 Last

Share
Profile

Follow
stevo

12,871 Posts.

583

21/05/24

19:27

Post #: 73941295
Share

Originally posted by mrposhman: ↑

I've long felt KAR is mispriced hence my ownership of the shares.

In terms of the debt issue, it was stated very clearly what it was for. It was for repayment of the existing debt, but they were annoyed that the banks wouldn't give them the full $340m drawdown (only $274m) so they went looking for another source, but having access to the extra $66m, doesn't appear to be required when you look at the cash balances and the projected cash inflows in 2024. Any debt of a new acquisition can easily be sourced at the time of acquisition using a new RBL facility on the new assets.

Its practically certain that the old RBL will be extinguished, because security over the KAR subsidiaries has been provided to them, which is also the same security they would have provided for the RBL.

The only benefits of changing to bonds, was gaining an extra $66m in debt and removing the requirement to hedge which was a restriction of the RBL (only for circa 30% of production).
The downside is that the interest rate was higher.
The neutral position (as in, it can be taken as positive or negative) is that there is no repayment profile for the bonds (due at their expiry) whereas the RBL had repay provisions included to repay certain proportions on set dates. Positive as it retains the access to the cash for longer, negative in its retaining expensive debt without the ability to repay quicker so it prolongs the interest cycle.

Expand

Mr P, that’s very informative …thanks.

KAR Price at posting: $1.90 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

MXR

Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t

PCK

PainChek close to finding out if FDA approves its flagship app for use in dementia care

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 29 more messages in this thread...

First 83 Last

Add KAR (ASX) to my watchlist

(20min delay)
Last $1.62		Change 0.090(5.90%)		Mkt cap ! $1.299B

Open	High	Low	Value	Volume
$1.60	$1.65	$1.58	$7.843M	4.853M

Buyers (Bids)

No.	Vol.	Price($)
13	15755	$1.61

Sellers (Offers)

Price($)	Vol.	No.
$1.62	27327	14

View Market Depth

No.	Vol.	Price($)
16	33631	1.610
16	50460	1.605
19	136469	1.600
13	125372	1.595
11	96526	1.590

Price($)	Vol.	No.
1.615	47141	27
1.620	185901	26
1.625	146086	13
1.630	147444	14
1.635	63313	12

Last trade - 11.43am 02/10/2024 (20 minute delay)

KAR (ASX) Chart

Mr P, that’s very informative …thanks.

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t

PainChek close to finding out if FDA approves its flagship app for use in dementia care

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Mr P, that’s very informative …thanks.

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t

PainChek close to finding out if FDA approves its flagship app for use in dementia care

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News